Strategic Alliances and M&A

• Deerfield Management, in connection with its five-year partnership with Illumina, Inc. to apply a gene-based approach to the discovery and development of new treatments for diseases with unmet medical needs.
• Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.
• Merck & Co. in connection with various M&A and strategic alliance transactions, most recently in connection with its strategic alliances with Amathus Therapeutics and Yumanity Therapeutics.
• Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, in its acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio.
• Sony Corporation in connection with various M&A transactions.

Venture Capital & Emerging Growth Companies

• Deerfield Management, in connection with various debt and minority equity investments.
• Apertura Gene Therapy, in its $67 million Series A financing and its foundational in-licenses from The Broad Institute of MIT and Harvard and Harvard Medical School.
• Loadsmart, a leading freight technology company, in its $200 million Series D financing.
• Neomorph, Inc., in its $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs.
• Jaguar Gene Therapy, LLC in connection with its $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.
• Axovia Therapeutics, Inc., an gene therapy company developing disease-transformative medicines for ciliopathies, in connection with its Series A financing.
• Orchestra BioMed, Inc., a biomedical innovation company, in connection with its $72 million Series B/B1 financings.
• Clearview AI, a leading facial recognition company, in connection with its $30 million Series B financing.
• Flex, a NYC-based FinTech company, in connection with its equity financings.
• Digitalis Ventures, as outside general counsel.

Cannabis Industry

• Canopy Growth Corporation, in connection with various M&A transactions, including its agreement to acquire Acreage Holdings and Wana Brands.
• Cresco Labs, in connection with various M&A transactions, including its announced acquisition of Columbia Care.
• The Scotts Miracle-Gro Company, in connection with its acquisition of Luxx Lighting, and its minority investment in RIV Capital.  
• RIV Capital, in connection with various investment transactions, including its announced acquisition of Etain.
• Turning Point Brands, in connection with various debt and minority equity investments.
• Tuatara Capital, in connection with various debt and minority equity investments.

• Moderator, "Early-Stage Company Pitfalls and Risk Considerations", the Cure Symposia by Deerfield, November 2021 
• Moderator, "Beyond the Science: What Principal Investigators (PIs) Need to Consider When Negotiating", the Cure Symposia by Deerfield, October 2021 
• Moderator, "The Future of Venture Capital", New York Venture Summit, July 2018
• Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018                                                          
• NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, Nov 2017 
• Plenary Session Moderator, "In Pursuit of Growth, Savings, and Return on Investment: Pharma’s Quest for Innovation Partnerships", Life Sciences Summit, November 2017
• Guest Lecturer, "Life Sciences Patent Law", NYU School of Law, April 2017
• Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
• Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
• Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017
• Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal, January 2017, Vol. 37 Issue 1
• Panelist, "Dealmaking 2017: Exploring Academic-Industry Partnerships", New York Pharma Forum, January 2017
• Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
• When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Shareholders, Law360, July 2016
• Legal Health Isn't Easy for Digital Health Companies, TechCrunch. April 2016.
• Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
• Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR,  The M&A Lawyer, January 2016.
• Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April 2015.
• The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014.